Monia Zaier
University of Sousse
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Monia Zaier.
Onkologie | 2012
Kmira Zahra; Wafa Ben Fredj; Yosra Ben Youssef; Houneida Zaghouani; Imène Chebchoub; Monia Zaier; Sriha Badreddine; Nejia Braham; Hlima Sennana; Abderrahim Khelif
Background: Philadelphia chromosome-positive chronic myeloid leukemia (CML) in children is very rare. CML occurring as a secondary malignancy in individuals treated for diffuse large B-cell lymphoma (DLBCL) is also rare. Case Report: We present the case of a 5-year-old female patient who developed a right orbital mass that was diagnosed as DLBCL. 9 months after receiving treatment for DLBCL, she presented with a white cell count of 250,000/mm3. Peripheral blood and bone marrow (BM) evaluation revealed a myeloproliferative disorder. Cytogenetic and molecular studies demonstrated the presence of t(9;22). CML following DLBCL has not been previously described in the younger population. To our knowledge, this is the first report of a child who developed a CML as a second malignancy after DLBCL. Therapy-related CML and non-therapy-related secondary CML are discussed as potential explanations of this highly unusual clinical presentation. Conclusion: Hematological disorders such as CML may occur after lymphomas. With the increased use of BM cytogenetic studies during staging for lymphoid malignancies, future studies may be able to clarify the question of whether the CML clone in some of these patients existed before treatment for lymphoma.
Hereditary Cancer in Clinical Practice | 2011
Rim El Abed; Violaine Bourdon; Ilia Voskoboinik; Halima El Omri; Yosra Ben Youssef; Mohamed Adnène Laatiri; Laetitia Huiart; François Eisinger; Laetitia Rabayrol; Marc Frenay; Paul Gesta; Liliane Demange; Hélène Dreyfus; Valérie Bonadona; Catherine Dugast; Hélène Zattara; Laurence Faivre; Monia Zaier; Saloua Yacoub Jemni; Testsuro Noguchi; Hagay Sobol; Zohra Soua
Perforin gene (PRF1) mutations have been identified in some patients diagnosed with the familial form of hemophagocytic lymphohistiocytosis (HLH) and in patients with lymphoma. The aim of the present study was to determine whether patients with a familial aggregation of hematological malignancies harbor germline perforin gene mutations. For this purpose, 81 unrelated families from Tunisia and France with aggregated hematological malignancies were investigated. The variants detected in the PRF1 coding region amounted to 3.7% (3/81). Two of the three variants identified were previously described: the p.Ala91Val pathogenic mutation and the p.Asn252Ser polymorphism. A new p.Ala 211Val missense substitution was identified in two related Tunisian patients. In order to assess the pathogenicity of this new variation, bioinformatic tools were used to predict its effects on the perforin protein structure and at the mRNA level. The segregation of the mutant allele was studied in the family of interest and a control population was screened. The fact that this variant was not found to occur in 200 control chromosomes suggests that it may be pathogenic. However, overexpression of mutated PRF1 in rat basophilic leukemia cells did not affect the lytic function of perforin differently from the wild type protein.
Annales De Biologie Clinique | 2013
Yosra Ben Youssef; Abir Gmidène; Zahreddine Bouabid; Sonia Bouallegui; Badreddine Sriha; Monia Zaier; Hlima Sennana; Abserrahim Khelif
The association of essential thrombocythemia and multiple myeloma is extremely rare, with only three patients previously treated with hydroxyurea reported in the literature until now. In this paper, we report the case of a 66 year old male who developed IgG-kappa M six years after the diagnosis of essential thrombocythemia, for which he had received hydroyurea. The possible etiological and pathogenic link between both these entities is here discussed.
Revue Neurologique | 2016
Kmira Zahra; Rania Bouneb; Mohamed Mahjoub; H. Zaghouani; Monia Zaier; Y. Ben Youssef; Abderrahim Khelif
Acute lymphoblastic leukemia (ALL) is one of the most common haematological malignancies of childhood treated with methotrexate (MTX), as it crosses the blood–brain barrier [1]. The toxic effects of MTX are myelosuppression, mucositis, nephrotoxicity, hepatotoxicity, and neurotoxicity with acute or chronic encephalopathy [2,3]. Acute encephalopathy usually occurred within 5–14 days after intrathecal or high dose (HD) MTX and may include headache, nausea, altered mental status, blurred vision, aphasia, and hemiparesis. Transient acute encephalopathy has been clinically observed in 3–15 % of cancer patients after HD MTX [3,4]. MR imaging with diffusion-weighted (DW) imaging is used to identify acute stroke and to differentiate nonstroke conditions from ischemia [3,5]. We hereby report on a patient who developed acute cerebellar syndrome after combined HD MTX (5 g/m) and intrathecal MTX administration and recovered within 4 days. The first report of a case with intrathecal MTX-induced acute cerebellar syndrome was described in Turkey [6]. This is to our knowledge the second report of a case with MTX-induced acute cerebellar syndrome.
International journal of medical and pharmaceutical case reports | 2016
Kmira Zahra; Rania Bouneb; Sarra Mestiri; Mohamed Mahjoub; Monia Zaier; Yosra Ben Youssef; Abderrahim Khelif
Introduction: Mantle cell lymphoma (MCL) is a distinct entity within the World Health Organization classification of lymphoid neoplasm and represents approximately 8% of lymphoma. Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multiple lymph nodes as well as the spleen, bone marrow, blood, and gastrointestinal tract. MCL of the thyroid occurs exceptionally. The MCL of the stomach is also an exceptional occurrence. Observation: We describe the case of a 58-year-old male who was diagnosed with thyroid and gastric MCL. The patient was classified into high risk group according to the Mantle Cell Lymphoma International Prognostic Index (MIPI). The R-CHOP (Rituximab, Cyclophosphamide, Adriablastine, Vincristine and Prednisone) regimen was started and complete remission was achieved after 8 Case Study Zahra et al.; IJMPCR, 8(1): 1-6, 2016; Article no.IJMPCR.29229 2 courses. He currently receives a maintenance treatment with rituximab every two months. Conclusion: This case is a combination of two rather infrequent extranodal localizations of the MCL.
Medical Oncology | 2013
Ayda Bennour; Ines Ouahchi; B. Achour; Monia Zaier; Yosra Ben Youssef; Abderrahim Khelif; Ali Saad; Halima Sennana
Medical Oncology | 2013
Ayda Bennour; Ikram Tabka; Yosra Ben Youssef; Monia Zaier; Sondess Hizem; Abderrahim Khelif; Ali Saad; Halima Sennana
Medical Oncology | 2012
Ayda Bennour; Ines Ouahchi; Yosra Ben Youssef; Monia Zaier; Mohamed Adnène Laatiri; Imed Harrabi; Balkis Meddeb; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Medical Oncology | 2012
Ayda Bennour; Halima Sennana; Monia Zaier; Ines Ouahchi; Zannouba Mrad; Yosra Ben Youssef; Abderrahim Khelif; Ali Saad
International journal of medical and pharmaceutical case reports | 2016
Neila Fathallah; Kmira Zahra; Rania Bouneb; Mohamed Mahjoub; Wafa Guetari; Monia Zaier; Chaker Ben Salem; Abderrahim Khelif